Skip to Content

Strongbridge Biopharma plc

Merger

  • Date:
  • 5/24/2021
  • Company Name:
  • Strongbridge Biopharma plc
  • Stock Symbol:
  • SBBP
  • Company Name - Buyer:
  • Xeris Pharmaceuticals, Inc.
  • Stock Symbol - Buyer:
  • XERS
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 5/24/2021

Case Finder

Locate any case using the tools below.

NEW YORK, May 24, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Strongbridge Biopharma plc (NASDAQ: SBBP) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS).

On May 24, 2021, Strongbridge announced that it had signed an agreement to be acquired by Xeris for approximately $267 million.  Pursuant to the merger agreement, Strongbridge stockholders will receive 0.7840 shares of Xeris common stock plus one Contingent Value Right (“CVR”) worth up to $1 in cash or Xeris common stock.  The CVR will be paid out to Strongbridge stockholders if certain achievements are met.  The deal is scheduled to close in the fourth quarter of 2021.

Bragar Eagel & Squire is concerned that Strongbridge’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Strongbridge’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Strongbridge Biopharma plc. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: